InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.150 0.045 (42.86%)+
Announcement
Release
22 May 2026 3:18PM
Price at Release
$0.105
Full Release
download
Summary
Vectus Biosystems Limited announced a $0.8 million placement to accelerate their VB0004 clinical trial and other drug programs. The placement involves issuing 7,910,000 new fully paid ordinary shares at $0.10 per share to institutional and sophisticated investors, with each share accompanied by an option exercisable at $0.20. The funds raised will be used to advance the company's Phase IB clinical trial for VB0004, which targets fibrosis in the lungs, heart, and kidneys, as well as to support general working capital and the development of other drug compounds. Gleneagle Securities acted as the Lead Manager for the placement. The company expects the new shares to be quoted on the ASX around 27 May 2026. This strategic financial move is designed to strengthen Vectus' balance sheet and support its clinical and drug development efforts.
Key Points
  • $0.8 million placement to accelerate VB0004 clinical trial.
  • 7,910,000 new shares at $0.10 per share.
  • Each share comes with an option exercisable at $0.20.
  • Funds will accelerate Phase IB trial for VB0004.
  • Placement will support other drug programs and working capital.
  • New shares expected on ASX by 27 May 2026.
  • Gleneagle Securities appointed as Lead Manager.
  • Strengthens balance sheet for clinical and drug development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.